The A2M Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population, generated by targeted disruption of the A2M gene in the Huh-7 human hepatocellular carcinoma cell line. This polyclonal pool comprises a heterogeneous mixture of edited alleles, providing a robust loss-of-function model for alpha-2-macroglobulin. The format circumvents clonal selection bias, ensuring that the resulting population better reflects the natural genetic diversity of the parental line while reliably abolishing A2M protein expression.
The Huh-7 cell line was derived from a well-differentiated hepatocellular carcinoma of a 57-year-old Japanese male and is extensively employed as a hepatocyte surrogate. Huh-7 cells maintain hepatic characteristics, including cytochrome P450 activity for drug metabolism, plasma protein secretion, and susceptibility to hepatitis C virus infection. Accordingly, they are widely adopted for hepatic metabolism, detoxification, drug toxicity, and viral replication studies, and their tumor origin renders them applicable to liver cancer research.
A2M encodes alpha-2-macroglobulin, a homotetrameric pan-protease inhibitor that traps a broad spectrum of proteases??such as trypsin, plasmin, and thrombin??via a bait region mechanism. Trapped proteases are cleared by LRP1 receptor-mediated endocytosis. A2M also binds and sequesters cytokines, particularly TGF-beta, modulating its bioavailability and downstream signaling. A2M transcription is driven by IL-6-activated STAT3, IL-1, TNF-alpha, oncostatin M, and glucocorticoids, linking it to the acute phase response. Through these interactions, A2M influences NF-kB pathway activity and cytokine clearance, thereby connecting proteolytic regulation to inflammatory and fibrotic outcomes.
In the Huh-7 hepatocellular carcinoma context, A2M knockout permits detailed examination of protease- and cytokine-dependent tumor progression mechanisms. Elimination of A2M likely shifts the balance of TGF-beta activity, impacting processes such as epithelial-mesenchymal transition, cell migration, and invasion. The acute phase responsiveness of Huh-7 cells further allows investigation of IL-6/STAT3-driven inflammatory signaling and its modulation by A2M. Additionally, this model aids in evaluating drug-induced hepatotoxicity, where release of proteases and dysregulation of cytokine networks are critical determinants of cellular damage.
This polyclonal knockout model is ideally suited for a range of research applications, including investigating protease roles in hepatocellular carcinoma, analyzing TGF-beta sequestration and its effects on tumor plasticity, dissecting acute phase signaling cascades, and performing drug metabolism and toxicity studies. It also serves as a platform for HCV replication experiments exploring host protease networks. Compatible assays include Western blotting, RT-qPCR, protease activity and ELISA assays, co-immunoprecipitation, cell viability and migration/invasion assays, and flow cytometry for LRP1 expression. For further technical information or purchase inquiries, please contact Ascent Research.
